Canaccord Genuity Reiterates a 'Hold' on Momenta Pharmaceuticals (MNTA); Q2: First Clarity on Baxter (BAX) Biosimilars Deal

Canaccord Genuity reiterates a 'Hold' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $12.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on lack of near--term catalysts but long--term biosimilars potential remains. M-enox revenues are now a modest royalty stream, and M356 generic Copaxone launch is delayed until 2016. While MNTA's Baxter-partnered (NYSE: BAX) biosimilars program and branded drugs have significant long-term potential, lack of near-term catalysts likely limits 12- month upside."

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $14.12 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group
• Beike (BEKE) PT Raised to $23 at Morgan Stanley